A Newly Diagnosed CML-CP HBV Carrier was Safely Treated with Dasatinib and Entecavir

Abstract

Oral administration of multikinase inhibitor dasatinib showed significantly higher and faster rates of CCyR and MMR than imatinib in patients with newly diagnosed chronic myeloid leukemina (CML)-chronic phase (CP). The reactivation of hepatitis B virus (HBV) is a well-known complication for HBV carrier treated with cytotoxic or immunosuppressive agent. Although dasatinib may act as an immunosuppressive agent, it is unclear whether dasatinib induces the reactivation of HBV. Here, we report the combination therapy with dasatinib and entecavir in newly diagnosed CML-CP patient with HBV carrier. A 63-year-old man with HBV carrier newly diagnosed as CML-CP. HBV DNA levels in serum showed 2.4 log copies/ml. Before administration of dasatinib, the patient received 0.5mg of entecavir daily. Six days later, HBV DNA levels decreased less than 2.1 log copies/ml. Then, 100mg of dasatinib was administrated in combination with entecavir daily. Partial cytogenic response was achieved at day 90. At one year, major molecular response was achieved. Neither adversed events (AEs) of liver function nor evidence of reactivation of HBV was observed. Combination with entecavir and dasatinib is safe and effective therapy for newly diagnosed CML-CP with HBV carrier. Accumulation of such cases is necessary to optimize the treatment approach.